Inari is offering 7,333,000 shares of its common stock. In addition, Inari expects to grant the underwriters a 30-day option to purchase up to an additional 1,099,950 shares of its common stock.
This funding will enable RetiSpec to accelerate the commercialization of its groundbreaking technology aimed at early detection of Alzheimer's disease.
